Show simple item record

dc.contributor.authorPrichard, R S
dc.contributor.authorCotter, M
dc.contributor.authorEvoy, D
dc.contributor.authorGibbons, D
dc.contributor.authorCollins, C
dc.contributor.authorMcDermott, E
dc.contributor.authorSkehan, S
dc.date.accessioned2012-02-01T10:31:27Z
dc.date.available2012-02-01T10:31:27Z
dc.date.issued2012-02-01T10:31:27Z
dc.identifier.citationIr Med J. 2011 Jun;104(6):177-9.en_GB
dc.identifier.issn0332-3102 (Print)en_GB
dc.identifier.issn0332-3102 (Linking)en_GB
dc.identifier.pmid22111394en_GB
dc.identifier.urihttp://hdl.handle.net/10147/207563
dc.description.abstractFluorodeoxyglucose (FDG) whole body positron emission computed tomography (PET-CT) detects clinically occult malignancy. The aim of this study was to assess the prevalence and significance of focal thyroid 18F - fluorodeoxyglucose uptake. A retrospective review of all patients who had FDG PET-CT examinations, in a single tertiary referral centre was performed. PET scan findings and the final pathological diagnosis were collated. 2105 scans were reviewed. Focal uptake was identified in 35 (1.66%) patients. Final surgical histology was available on eight patients, which confirmed papillary carcinoma in four (20%) patients and lymphoma and metastatic disease in two patients respectively. This gave an overall malignancy rate in focal thyroid uptake of at least 33%. Thyroid incidentalomas occurred with a frequency of 2.13%, with an associated malignancy rate of at least 33% in focal thyroid uptake. The high malignancy rate associated with focal thyroid uptake mandates further investigation in medically fit patients.
dc.language.isoengen_GB
dc.subject.meshAgeden_GB
dc.subject.meshCarcinoma, Papillary/pathology/radionuclide imagingen_GB
dc.subject.meshFemaleen_GB
dc.subject.meshFluorodeoxyglucose F18/diagnostic useen_GB
dc.subject.meshHumansen_GB
dc.subject.mesh*Incidental Findingsen_GB
dc.subject.meshMaleen_GB
dc.subject.meshMiddle Ageden_GB
dc.subject.mesh*Positron-Emission Tomography and Computed Tomographyen_GB
dc.subject.meshRadiopharmaceuticals/diagnostic useen_GB
dc.subject.meshRetrospective Studiesen_GB
dc.subject.meshThyroid Neoplasms/pathology/*radionuclide imagingen_GB
dc.subject.mesh*Whole Body Imagingen_GB
dc.titleFocal thyroid incidentalomas identified with whole-body FDG-PET warrant further investigation.en_GB
dc.contributor.departmentSt Vincent's University Hospital, Elm Park, Dublin 4 ruthprichard@rcsi.ieen_GB
dc.identifier.journalIrish medical journalen_GB
dc.description.provinceLeinster
html.description.abstractFluorodeoxyglucose (FDG) whole body positron emission computed tomography (PET-CT) detects clinically occult malignancy. The aim of this study was to assess the prevalence and significance of focal thyroid 18F - fluorodeoxyglucose uptake. A retrospective review of all patients who had FDG PET-CT examinations, in a single tertiary referral centre was performed. PET scan findings and the final pathological diagnosis were collated. 2105 scans were reviewed. Focal uptake was identified in 35 (1.66%) patients. Final surgical histology was available on eight patients, which confirmed papillary carcinoma in four (20%) patients and lymphoma and metastatic disease in two patients respectively. This gave an overall malignancy rate in focal thyroid uptake of at least 33%. Thyroid incidentalomas occurred with a frequency of 2.13%, with an associated malignancy rate of at least 33% in focal thyroid uptake. The high malignancy rate associated with focal thyroid uptake mandates further investigation in medically fit patients.


This item appears in the following Collection(s)

Show simple item record